EFFECT - Mural Oncology plc (0001971543) (Filer)

S-8 POS - Mural Oncology plc (0001971543) (Filer)

S-8 POS - Mural Oncology plc (0001971543) (Filer)

S-8 POS - Mural Oncology plc (0001971543) (Filer)

POS AM - Mural Oncology plc (0001971543) (Filer)

25-NSE - Mural Oncology plc (0001971543) (Subject)

8-K - Mural Oncology plc (0001971543) (Filer)

SCHEDULE 13G/A - Mural Oncology plc (0001971543) (Subject)

144 - Mural Oncology plc (0001971543) (Subject)

144 - Mural Oncology plc (0001971543) (Subject)

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc ("Mural") (NASDAQ:MURA) (the "Acquisition") pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme"). Mural shareholders received $2.035 in cash per share (the "Consideration"). The Acquisition was approved by Mural shareholders at a special meeting of shareholders convened pursuant to section 450(1) of the Ir

WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the "Effective Date"). Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon

WALTHAM, Mass. and DUBLIN, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural") announces that the High Court of Ireland has today sanctioned the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the "Scheme") pursuant to which XRA 5 Corp. ("Sub"), a wholly-owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), will acquire the entire issued and to be issued share capital of Mural (the "Acquisition"). The Scheme and the Acquisition will become effective on delivery of the Court Order to the Irish Registrar of Companies. Delivery of the Court Order to the Irish Registrar of Companies

WALTHAM, Mass. and DUBLIN, Ireland, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") announces that, in accordance with the terms of the transaction agreement between XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"), XRA 5 Corp. ("Sub") and Mural announced on August 20, 2025 (the "Transaction Agreement"), the Additional Price Per Share (as defined in the Transaction Agreement) has been finally determined in accordance with Clause 2.4 of the Transaction Agreement as $0.000. As a result, the total cash consideration payable to Mural shareholders on closing of the Acquisition (as defined below) will be $2.035 in cash per share. As previously announced on Au

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION  WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. ("Sub"), a wholly owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"). As described in more detail below, a majority in number of the shareholders of record present and voting, either in person or by proxy and more than 99 perc

WALTHAM, Mass. and DUBLIN, Ireland, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (NASDAQ:MURA) ("Mural"), a clinical-stage immuno-oncology company, today announces for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2022 (the "Irish Takeover Rules"), that it has published the definitive proxy statement of Mural relating to the Acquisition described below, which also constitutes a scheme circular under Irish law (the "Proxy Statement") and that Mural has commenced mailing the Proxy Statement to Mural shareholders. As previously announced on August 20, 2025, XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty") and Mural entered into a definitive transaction

WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol

Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), today announced its financial results for the second quarter of 2025 and provided a business update. On April 15, 2025, Mural announced that it was discontinuing all clinical development of its lead product candidate, nemvaleukin alfa, and was commencing the exploration of strategic alternatives focused on maximizing shareholder value. The Company is continuing to explore

Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.4 million in cash as of December 31, 2024, Mural plans to explore strategic alternatives and will undertake a reduction in force of approximately 90% of employees WALTHAM, Mass. and DUBLIN, April 15, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company, today announced that following review of data from its phase 2 ARTISTRY-6 trial in melanoma and previously announced results from the phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer

Based on overall survival data observed in interim analysis in platinum-resistant ovarian cancer, Mural will not progress trial to final analysis Continued demonstration of favorable tolerability profile generally consistent with previously reported data; over 800 patients treated across the greater nemvaleukin clinical program The company remains on track to share topline results from potentially registrational, phase 2 trial in mucosal melanoma, ARTISTRY-6, Cohort 2, evaluating nemvaleukin monotherapy in Q2 2025 WALTHAM, Mass and DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company, today announced that the ARTISTR

4 - Mural Oncology plc (0001971543) (Issuer)

Morgan Stanley downgraded Mural Oncology from Overweight to Equal-Weight

Raymond James downgraded Mural Oncology from Strong Buy to Outperform and set a new price target of $18.00

Rodman & Renshaw initiated coverage of Mural Oncology with a rating of Buy and set a new price target of $15.00

Morgan Stanley initiated coverage of Mural Oncology with a rating of Overweight and set a new price target of $13.00

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

4 - Mural Oncology plc (0001971543) (Issuer)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION  WALTHAM, Mass. and DUBLIN, Ireland, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA) ("Mural") today announced that its shareholders have voted to approve the previously announced proposed acquisition of Mural by XRA 5 Corp. ("Sub"), a wholly owned subsidiary of XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty"). As described in more detail below, a majority in number of the shareholders of record present and voting, either in person or by proxy and more than 99 perc

WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company ("Mural"), and XOMA Royalty Corporation (NASDAQ:XOMA), a biotechnology royalty aggregator ("XOMA Royalty"), announced today they have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly formed company wholly owned by XOMA Royalty ("Sub"), has agreed to acquire the entire issued and to be issued share capital of Mural for cash (the "Acquisition") subject to the satisfaction of the closing conditions set out in Appendix I of this Announcement (the "Conditions"), including approval by Mural Shareholders. Fol

Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), today announced its financial results for the second quarter of 2025 and provided a business update. On April 15, 2025, Mural announced that it was discontinuing all clinical development of its lead product candidate, nemvaleukin alfa, and was commencing the exploration of strategic alternatives focused on maximizing shareholder value. The Company is continuing to explore

Interim analysis of overall survival in potentially registrational phase 3 ARTISTRY-7 trial in platinum-resistant ovarian cancer expected in late Q1/early Q2 2025 Top-line data readout of potentially registrational phase 2 ARTISTRY-6 (cohort 2) trial in mucosal melanoma expected in Q2 2025 Preliminary data readouts for less-frequent intravenous dosing of nemvaleukin alfa in the ARTISTRY-6 trial in patients with cutaneous melanoma expected in 1H 2025 for monotherapy (cohort 3) and 2H 2025 for combination therapy (cohort 4) Cash runway extended into Q1 2026 through operational efficiencies WALTHAM, Mass. and DUBLIN, March 11, 2025 (GLOBE NEWSWIRE) -- Mural Oncolog

Lead product candidate, nemvaleukin, is being developed to treat a wide range of solid tumors and is currently in two potentially registrational clinical trials with readouts for both expected in 1H 2025 Newly recommended phase 2 dose of nemvaleukin with increased dosage and less frequent dosing schedule to be explored in a cohort of ARTISTRY-6, the company's ongoing phase 2 trial in patients with melanoma Mural Oncology intends to nominate development candidates for its engineered therapies targeting interleukin-18 and interleukin-12 in 2024 The company reiterates cash runway projection into 4Q 2025 WALTHAM, Mass. and DUBLIN, Ireland, March 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology

Company remains on track in late-stage, potentially registrational trials of nemvaleukin alfa, with data readouts expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Candidate nominations for IL-18 and IL-12 programs expected in Q4 2024, and IND submission for Mural's IL-18 program planned for Q4 2025 Mural reiterates guidance on projected cash runway into Q4 2025 WALTHAM, Mass. and DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of can

Key data readouts for the company's late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Management team to provide additional information not previously disclosed related to nemvaleukin study design, statistical assumptions, and study execution Clinicians to discuss treatment landscape of platinum-resistant ovarian cancer and mucosal melanoma, two indications with limited treatment options and poor outcomes for patients IND submission for Mural's IL-18 program planned for Q4 2025 WALTHAM, Mass and DUBLIN, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MUR

WALTHAM, Mass and DUBLIN, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of Sachiyo Minegishi to its board of directors, effective September 20. Ms. Minegishi will serve as Chair of the Audit Committee and will also be joining the company's Nominating and Corporate Governance Committee. "With over 20 years of industry experience, Sachiyo brings a successful record of helping companies navigate through important clinical, financial, and corporate mileston

WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (NASDAQ:MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced the appointment of George Golumbeski, Ph.D., to its board of directors effective July 30. "George has been a leader in business development for 30 years. There has been a great deal of industry interest in cytokine programs as of late, and Mural is in the fortunate position of having two potentially registrational studies reading out in the first half of 2025, as well as two preclinical programs hea

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)

SC 13G/A - Mural Oncology plc (0001971543) (Subject)